eTable 1. Correlations between serum cytokine levels and clinical and radiological characteristics at baseline.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Marker** | **Durationa**  | **Relapsesb**  | **EDSS**  | **T2 lesionsc**  | **Gd+ lesionsc** |
| IL-6 | -0.136 (0.278) | 0.163 (0.192) | 0.158 (0.206) | 0.041 (0.741) | 0.101 (0.420) |
| IL-17 | -0.071 (0.571) | -0.079 (0.528) | -0.175 (0.160) | -0.007 (0.955) | 0.000 (0.997) |
| TNF- | 0.084 (0.501) | -0.106 (0.397) | -0.062 (0.622) | -0.045 (0.721) | 0.073 (0.559) |
| GM-CSF | 0.232 (0.061) | -0.219 (0.077) | 0.117 (0.349) | 0.095 (0.449) | -0.149 (0.232) |
| IL-10 | -0.010 (0.938) | 0.089 (0.476) | **-0.350 (0.004)** | -0.114 (0.363) | -0.067 (0.595) |
| IFN- | 0.143 (0.252) | -0.073 (0.563) | -0.040 (0.751) | 0.027 (0.830) | -0.030 (0.809) |
| IL-1 | 0.030 (0.809) | -0.130 (0.297) | 0.023 (0.857) | 0.190 (0.127) | -0.126 (0.312) |
| CXCL13 | -0.074 (0.553) | -0.191 (0.124) | 0.014 (0.910) | 0.059 (0.640) | -0.045 (0.721) |

#### Data are expressed as Spearman correlation coefficient (p value). aDisease duration was calculated as the difference between disease onset and treatment onset. bRefers to the number of relapses in the two years before treatment onset. cRefers to the number of T2 lesions and gadolinium enhancing (Gd+) lesions.